Back to User profile » Dr Michael Broder
Papers published by Dr Michael Broder:
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
Gertz M, Abonour R, Gibbs SN, Finkel M, Landau H, Lentzsch S, Lin G, Mahindra A, Quock T, Rosenbaum C, Rosenzweig M, Sidana S, Tuchman SA, Witteles R, Yermilov I, Broder MS
ClinicoEconomics and Outcomes Research 2023, 15:673-680
Published Date: 11 September 2023
Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
Greene N, Higuchi K, Bognar K, Chang E, Broder MS
ClinicoEconomics and Outcomes Research 2022, 14:755-761
Published Date: 22 December 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
Husni ME, Chang E, Broder MS, Paydar C, Bognar K, Desai P, Klyachkin Y, Khilfeh I
Open Access Rheumatology: Research and Reviews 2022, 14:123-132
Published Date: 15 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
An Adaptation of the RAND/UCLA Modified Delphi Panel Method in the Time of COVID-19
Broder MS, Gibbs SN, Yermilov I
Journal of Healthcare Leadership 2022, 14:63-70
Published Date: 20 May 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Development of a Severity Classification System for Sickle Cell Disease
Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Gordeuk VR, Kanter J, Klings ES, Lipato T, Manwani D, Scullin B, Yermilov I, Smith WR
ClinicoEconomics and Outcomes Research 2020, 12:625-633
Published Date: 28 October 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
Yan T, Greene M, Chang E, Houle CR, Tarbox MH, Broder MS
ClinicoEconomics and Outcomes Research 2020, 12:81-89
Published Date: 7 February 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States
Quock TP, Yan T, Tieu R, D'Souza A, Broder MS
ClinicoEconomics and Outcomes Research 2019, 11:431-439
Published Date: 15 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, Turpcu A
Clinical Ophthalmology 2018, 12:1625-1635
Published Date: 30 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis
Luskin AT, Antonova EN, Broder MS, Chang EY, Omachi TA, Ledford DK
ClinicoEconomics and Outcomes Research 2016, 8:641-648
Published Date: 25 October 2016
![Noteworthy comment: This study was conducted to estimate the clinical and economic impact that remains associated with uncontrolled surgical bleeding, even when hemostats are used during surgery. Uncontrolled intraoperative bleeding despite hemostat use is prevalent and associated with significantly higher hospital costs and worse clinical outcomes across several surgical procedures compared to controlled bleeding. There is an unmet need for newer hemostats that can more effectively control bleeding, improve outcomes, and reduce hospital resource use.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database
Corral M, Ferko N, Hollmann S, Broder MS, Chang E
ClinicoEconomics and Outcomes Research 2015, 7:409-421
Published Date: 22 July 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
Juday T, Correll T, Anene A, Broder MS, Ortendahl J, Bentley T
ClinicoEconomics and Outcomes Research 2013, 5:437-445
Published Date: 2 September 2013